ImmunoGen Message Board - Msg: 14731859

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sonny who wrote (3661)	11/5/2000 6:49:50 PM
From: RJMC	Read Replies (1) of 5665

You're probably right. One thing I do notice however is with regard to the other stocks that MTSL covers, that they don't seem to be using the same valuation philosophy (such as the STEM Cells recommendation, a company which doesn't even have anything in the pre-clinical stages yet). I noticed that MTSL is quick to raise buy and target limits for the other stocks. But there seems to be a dichotomy when it comes to IMGN. It's hard to imagine IMGN staying in the existing price range. Seems like any kind of news saying that everything is at least going as well as expected in clinical's will drive it up at least 10-20 points (probably a lot more if the news is significant). Any bad news, which is unlikely to the extreme given what Dr. Tolcher said in the IBD article, and the stock wouldn't even be worth recommending. MTSL has always had a history of sticking their necks out with recommendations on good technology. It's just hard for me to see what's holding them back right now. Gonna be a big week, one way or the other. Bob M.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next